Print Page     Close Window     

SEC Filings

20-F
AC IMMUNE SA filed this Form 20-F on 03/21/2019
Entire Document
 

Convertible Note Agreement | AC Immune SA, 11 December 201821/23

Annex 2

 

AC Immune SA 

Attn. Prof. Dr. Andrea Pfeifer 

CEO 

EPFL Innovation Park Building B 

1015 Lausanne, Switzerland

 

Place, Date:     

 

 

Conversion Notice

 

 

 

Dear Prof. Dr. Andrea Pfeifer,

 

We refer to the convertible note agreement dated 11 December 2018 (the “Agreement”) between AC Immune SA as borrower and our company Eli Lilly and Company as lender. 

 

Capitalized terms used in this Conversion Notice but not otherwise defined herein shall have the meaning ascribed to them in the Agreement.

 

In full knowledge of the Borrower’s articles of association, we hereby:

 

1.acknowledge the conversion of the Loan and the interest due, in accordance with Article 5 of the Agreement for an amount corresponding to our claim against the Borrower as per [date] under the Agreement, i.e., USD [amount], into [number] common shares (the “Relevant Shares”) in the Borrower; and

 

2.request the Borrower to provide us with the Borrower’s commercial register excerpt giving evidence of the issuance of Relevant Shares.

 

 

 

Eli Lilly and Company
 
 
 

Name:

 

Function:

  

 

 


© AC Immune 2015